MK0869, aprepitant

ApprovedSmall molecule

MK0869, aprepitant is one of 106 small molecule programs targeting Chemotherapy-induced nausea and vomiting. It is currently in Approved.

Indications

Total Trials

Active Trials

105

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chemotherapy-Induced Nausea and VomitingActive, not recruiting

Nausea and VomitingActive, not recruiting

Major Depressive DisorderActive, not recruiting

Chemotherapy-Induced Nausea and VomitingPhase 3

Active, not recruiting

Nausea and VomitingApproved

Active, not recruiting

Major Depressive DisorderPhase 3

Active, not recruiting

Competition

Competitive Landscape

386 competitors in Major Depressive Disorder

#DrugCompanyPhaseTrials

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

12 2

Elavil

AstraZeneca

Phase 3

2 3

Daliresp

AstraZeneca

Phase 3

1 4

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

5 5

Nuplazid

AACADIA Pharmaceuticals Inc.

Phase 3

4 6

Ketalar

Boehringer Ingelheim

Phase 3

3 7

Latuda

SSunovion Respiratory Development Inc.

Phase 3

3 8

Versed

CConrado Roberto Hoffmann Filho

Phase 3

2 9

Celebrex

PPhiladelphia Eye Associates

Phase 3

2 10

Risperdal

WWim Janssens

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Major Depressive Disorder4 trials

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00042029·324 enrolled

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00035295·584 enrolled

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00035009·468 enrolled

Show 1 more trial

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00034944·495 enrolled

Nausea and vomiting3 trials

Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT00090207·477 enrolled

2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00090155·805 enrolled

2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00090246·922 enrolled

Chemotherapy-induced nausea and vomiting2 trials

Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00092196·820 enrolled

An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT00092183·866 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for MK0869, aprepitant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MK0869, aprepitant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MK0869, aprepitant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Merck & Co.

MK0869, aprepitant

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Major Depressive Disorder4 trials

Nausea and vomiting3 trials

Chemotherapy-induced nausea and vomiting2 trials

References

Drug Info

Quick Facts

Related News